Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Share-based Compensation (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Share-based Compensation for 13 consecutive years, with $25.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Share-based Compensation rose 45.89% to $25.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $98.1 million, a 22.85% increase, with the full-year FY2025 number at $98.1 million, up 22.85% from a year prior.
  • Share-based Compensation was $25.8 million for Q4 2025 at Madrigal Pharmaceuticals, down from $26.3 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $26.3 million in Q3 2025 to a low of $6.1 million in Q1 2021.
  • A 5-year average of $14.3 million and a median of $12.0 million in 2023 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: dropped 2.87% in 2022, then skyrocketed 122.4% in 2024.
  • Madrigal Pharmaceuticals' Share-based Compensation stood at $6.4 million in 2021, then rose by 27.16% to $8.1 million in 2022, then skyrocketed by 83.77% to $14.9 million in 2023, then grew by 19.01% to $17.7 million in 2024, then soared by 45.89% to $25.8 million in 2025.
  • Per Business Quant, the three most recent readings for MDGL's Share-based Compensation are $25.8 million (Q4 2025), $26.3 million (Q3 2025), and $25.2 million (Q2 2025).